Immunome, Inc. (NASDAQ:IMNM) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lessened its position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 64.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 18,153 shares of the company's stock after selling 33,398 shares during the quarter. Jane Street Group LLC's holdings in Immunome were worth $193,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new position in Immunome during the fourth quarter valued at $75,000. AlphaQuest LLC lifted its position in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after buying an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after acquiring an additional 7,129 shares during the period. Aquatic Capital Management LLC purchased a new stake in Immunome in the 4th quarter worth approximately $95,000. Finally, Stoneridge Investment Partners LLC bought a new stake in Immunome during the 4th quarter worth approximately $123,000. Institutional investors own 44.58% of the company's stock.

Immunome Stock Performance

IMNM stock traded down $0.11 during midday trading on Monday, reaching $9.03. The company's stock had a trading volume of 244,169 shares, compared to its average volume of 918,078. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $16.81. The firm has a market capitalization of $785.28 million, a price-to-earnings ratio of -1.11 and a beta of 1.94. The stock has a fifty day simple moving average of $7.88 and a two-hundred day simple moving average of $9.50.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.14. The company had revenue of $2.93 million during the quarter, compared to analyst estimates of $0.46 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Clay B. Siegall bought 137,100 shares of the business's stock in a transaction on Wednesday, March 26th. The shares were bought at an average price of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the purchase, the chief executive officer now directly owns 806,736 shares of the company's stock, valued at approximately $5,881,105.44. This trade represents a 20.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jean Jacques Bienaime bought 5,000 shares of Immunome stock in a transaction on Tuesday, June 3rd. The stock was purchased at an average price of $9.38 per share, with a total value of $46,900.00. Following the completion of the acquisition, the director now directly owns 36,415 shares of the company's stock, valued at $341,572.70. This represents a 15.92% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 161,400 shares of company stock valued at $1,207,395 over the last 90 days. Corporate insiders own 8.60% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IMNM. Lifesci Capital initiated coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective for the company. Wedbush reissued an "outperform" rating and set a $21.00 price target (down from $33.00) on shares of Immunome in a report on Tuesday, May 13th. Guggenheim cut their target price on Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, March 20th. Stephens reissued an "overweight" rating and issued a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Finally, Lake Street Capital initiated coverage on Immunome in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 price target for the company. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $23.33.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.